September 20, 2013 - The court granted defendants' motion to dismiss and dismissed the case.
October 15, 2012 - The lead plaintiff filed an amended complaint.

August 14, 2012 - The court vacates the lead plaintiff and lead counsel order and a new lead plaintiff and lead counsel were appointed.

July 31, 2012 - Lead plaintiffs and lead counsel were appointed.

April 17, 2012 - Lead plaintiff motions were filed.

February 17, 2012 - An investor in shares of Metabolix Inc (NASDAQ: MBLX) filed a lawsuit in the U.S. District Court for the District of Massachusetts against Metabolix Inc over alleged false and misleading statements.

According to the complaint the plaintiff alleges on behalf of all persons or entities that purchased the common stock of Metabolix Inc (NASDAQ: MBLX) between March 10, 2010 and January 12, 2012, that Metabolix Inc and certain of its officers violated the Securities Exchange Act of 1934 by issuing allegedly materially false and misleading statements and omissions regarding Metabolix Inc's business and operations.

Metabolix Inc reported that its annual Revenue fell from $1.43million in ’09 to $0.45million in 2010 and its Net Loss increased from $37.96million for 2009 to $38.80million in 2010.

Specifically, the plaintiff alleges that defendants materially misrepresented and/or failed to disclose that Telles LLC, Metabolix Inc's joint venture with Archer-Daniels-Midland, which was established in July 2006 to sell PHA-based bioplastics, including Mirel and Mvera, in the US, Europe and other countries, would not meet its commercial phase benchmark by mid-2010, or even in 2011, which would allow the Metabolix to receive royalty payments and payments from services from Telles LLC, and that Metabolix Inc's polyhydroxyalkanoate bioplastics product under the brand name Mirel was not a commercially viable product.

Shares of Metabolix Inc (NASDAQ: MBLX) rose in 2010 to as high as $17.49 per share.

Then on January 12, 2012, Metabolix Inc announced that Archer-Daniels-Midland had terminated the Telles LLC joint venture because uncertainty about projected capital and production costs, and the rate of market adoption, caused too much uncertainty about projected financial returns for ADM. ADM further disclosed that the Telles joint venture was neither delivering sufficient results, nor was expected to deliver sufficient results in a reasonable timeframe. Upon this news, Metabolix Inc stock declined approximately 57%, to reach a multi-year low of $2.54 per share.

Then on January 12, 2012, Metabolix Inc (NASDAQ: MBLX) announced that the Archer Daniels Midland Company has given notice of termination of the Telles, LLC joint venture for PHA bioplastics.

Metabolix Inc said that the joint venture Archer Daniels Midland Company recently undertook a strategic review of its business investments and activities and made the decision to focus resources outside of Telles LLC.

Metabolix Inc said that as the basis for the decision, Archer Daniels Midland Company indicated that the projected financial returns from the alliance were too uncertain.

Shares of Metabolix Inc (NASDAQ: MBLX) dropped from almost $6 per share on January 12, 2012 to $2.54 on January 13, 2012 and closed on February 21, 2012 at $2.85 per share.